Overview

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.

Phase:

Phase 2

Details

Lead Sponsor:

Lexicon Pharmaceuticals

Collaborator:

Sanofi

Treatments:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol